• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

两种静脉注射用姜黄素制剂在 3D 患者来源肿瘤球体模型中的抗癌特性评价。

Anti-Cancer Properties of Two Intravenously Administrable Curcumin Formulations as Evaluated in the 3D Patient-Derived Cancer Spheroid Model.

机构信息

Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University Munich, Marchioninistraße 15, 81377 Munich, Germany.

German Cancer Consortium (DKTK), Partner Site Munich, Pettenkoferstraße 8a, 80336 Munich, Germany.

出版信息

Int J Mol Sci. 2024 Aug 5;25(15):8543. doi: 10.3390/ijms25158543.

DOI:10.3390/ijms25158543
PMID:39126111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11313667/
Abstract

Curcumin (Cur) is a heavily used complementary derived drug from cancer patients. Spheroid samples derived from 82 patients were prepared and treated after 48 h with two Cur formulations (CurA, CurB) in mono- and combination therapy. After 72 h, cell viability and morphology were assessed. The Cur formulations had significant inhibitory effects of -8.47% ( < 0.001), CurA of -10.01% (-50.14-23.11%, = 0.001) and CurB of -6.30% (-33.50-19.30%, = 0.006), compared to their solvent controls Polyethylene-glycol, β-Cyclodextrin (CurA) and Kolliphor-ELP, Citrate (CurB). Cur formulations were more effective in prostate cancer (-19.54%) and less effective in gynecological non-breast cancers (0.30%). CurA showed better responses in samples of patients <40 (-13.81%) and >70 years of age (-17.74%). CurB had stronger effects in metastasized and heavily pretreated tumors. Combinations of Cur formulations and standard therapies were superior in 20/47 samples (42.55%) and inferior in 7/47 (14.89%). CurB stimulated chemo-doublets more strongly than monotherapies (-0.53% vs. -6.51%, = 0.022) and more effectively than CurA (-6.51% vs. 3.33%, = 0.005). Combinations of Cur formulations with Artesunate, Resveratrol and vitamin C were superior in 35/70 (50.00%) and inferior in 16/70 (22.86%) of samples. Cur formulations were significantly enhanced by combination with Artesunate ( = 0.020). Cur formulations showed a high variance in their anti-cancer effects, suggesting a need for individual testing before administration.

摘要

姜黄素（Cur）是癌症患者广泛使用的一种源自草药的补充药物。从 82 名患者中提取的球体样本在 48 小时后用两种姜黄素制剂（CurA、CurB）进行单药和联合治疗。72 小时后，评估细胞活力和形态。两种姜黄素制剂的抑制效果显著，-8.47%（<0.001），CurA 为-10.01%（-50.14%至 23.11%，=0.001），CurB 为-6.30%（-33.50%至 19.30%，=0.006），与溶剂对照物聚乙二醇、β-环糊精（CurA）和 Kolliphor-ELP、柠檬酸盐（CurB）相比。姜黄素制剂在前列腺癌中的效果更强（-19.54%），在妇科非乳腺癌中的效果较弱（0.30%）。CurA 在<40 岁（-13.81%）和>70 岁（-17.74%）的患者样本中反应更好。CurB 在转移和预处理较多的肿瘤中效果更强。姜黄素制剂与标准疗法的联合治疗在 20/47 个样本中（42.55%）效果更好，在 7/47 个样本中（14.89%）效果更差。CurB 刺激化疗双联药物的效果强于单药治疗（-0.53%对-6.51%，=0.022），也强于 CurA（-6.51%对 3.33%，=0.005）。姜黄素制剂与青蒿琥酯、白藜芦醇和维生素 C 的联合治疗在 35/70 个样本中（50.00%）效果更好，在 16/70 个样本中（22.86%）效果更差。姜黄素制剂与青蒿琥酯联合使用效果显著增强（=0.020）。姜黄素制剂的抗癌效果差异很大，提示在给药前需要进行个体化检测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/b98490a65ffd/ijms-25-08543-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/50629f4430a4/ijms-25-08543-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/0b9b75c38b06/ijms-25-08543-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/8c5001ff11cc/ijms-25-08543-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/3a41d072327b/ijms-25-08543-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/868336680ac2/ijms-25-08543-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/d117a778ad90/ijms-25-08543-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/86a87f8b18af/ijms-25-08543-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/5e4cdf6e1bd3/ijms-25-08543-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/13ac5685d816/ijms-25-08543-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/1349ba2560be/ijms-25-08543-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/b98490a65ffd/ijms-25-08543-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/50629f4430a4/ijms-25-08543-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/0b9b75c38b06/ijms-25-08543-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/8c5001ff11cc/ijms-25-08543-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/3a41d072327b/ijms-25-08543-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/868336680ac2/ijms-25-08543-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/d117a778ad90/ijms-25-08543-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/86a87f8b18af/ijms-25-08543-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/5e4cdf6e1bd3/ijms-25-08543-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/13ac5685d816/ijms-25-08543-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/1349ba2560be/ijms-25-08543-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6011/11313667/b98490a65ffd/ijms-25-08543-g011.jpg

相似文献

1
Anti-Cancer Properties of Two Intravenously Administrable Curcumin Formulations as Evaluated in the 3D Patient-Derived Cancer Spheroid Model.两种静脉注射用姜黄素制剂在 3D 患者来源肿瘤球体模型中的抗癌特性评价。
Int J Mol Sci. 2024 Aug 5;25(15):8543. doi: 10.3390/ijms25158543.
2
Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.紫杉醇和姜黄素共同给药于新型阳离子 PEG 化非离子型脂质体制剂中表现出增强的协同抗肿瘤功效。
J Nanobiotechnology. 2018 Mar 23;16(1):28. doi: 10.1186/s12951-018-0351-4.
3
Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy.姜黄素引导的纳米疗法：一种用于乳腺癌治疗中靶向药物递送的脂质基纳米药物。
Drug Deliv. 2016 May;23(4):1420-5. doi: 10.3109/10717544.2015.1066902. Epub 2015 Jul 23.
4
Long-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In Vitro.具有高包封效率、稳定性及对胰腺腺癌细胞系体外抗癌活性的长循环载姜黄素脂质体制剂
PLoS One. 2016 Dec 9;11(12):e0167787. doi: 10.1371/journal.pone.0167787. eCollection 2016.
5
Characterization of multifunctional β-cyclodextrin-coated BiO nanoparticles conjugated with curcumin for CT imaging-guided synergetic chemo-radiotherapy in breast cancer.多功能β-环糊精包覆的 BiO 纳米粒子与姜黄素偶联用于乳腺癌 CT 成像引导协同化疗-放疗的特性研究。
Int J Pharm. 2024 Jun 25;659:124264. doi: 10.1016/j.ijpharm.2024.124264. Epub 2024 May 22.
6
Curcumin loaded on graphene nanosheets induced cell death in mammospheres from MCF-7 and primary breast tumor cells.载姜黄素的石墨烯纳米片诱导 MCF-7 细胞和原发性乳腺癌肿瘤细胞的球体细胞死亡。
Biomed Mater. 2021 Jun 17;16(4). doi: 10.1088/1748-605X/ac0400.
7
Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: In vitro and in vivo anti-tumor study.载药量高的姜黄素稳定纳米脂质体制剂的制备及表征：体内外抗肿瘤研究。
Int J Pharm. 2020 Apr 30;580:119211. doi: 10.1016/j.ijpharm.2020.119211. Epub 2020 Mar 7.
8
Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment.通过纳米胶束共递送多西他赛和姜黄素增强卵巢癌治疗。
Int J Nanomedicine. 2020 Dec 3;15:9703-9715. doi: 10.2147/IJN.S274083. eCollection 2020.
9
Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.多柔比星和姜黄素共递送的多肽纳米载体用于协同淋巴瘤治疗。
Sci Rep. 2020 May 12;10(1):7832. doi: 10.1038/s41598-020-64828-1.
10
Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer.姜黄素载药固体脂质纳米粒增强乳腺癌的抗癌效率。
Molecules. 2018 Jun 29;23(7):1578. doi: 10.3390/molecules23071578.

本文引用的文献

1
The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway.姜黄素在癌症中的作用：聚焦于PI3K/Akt信号通路。
Cancers (Basel). 2024 Apr 18;16(8):1554. doi: 10.3390/cancers16081554.
2
A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity.一种新型载姜黄素的薄膜喷雾能抑制 SARS-CoV-2 和流感病毒感染并增强黏膜免疫。
Virol J. 2024 Jan 23;21(1):26. doi: 10.1186/s12985-023-02282-x.
3
Anti-Cancer Effects of Artesunate in Human 3D Tumor Models of Different Complexity.青蒿琥酯在不同复杂性的人源 3D 肿瘤模型中的抗癌作用。
Int J Mol Sci. 2023 Apr 25;24(9):7844. doi: 10.3390/ijms24097844.
4
Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials.探索姜黄素对癌症治疗的贡献：随机对照试验的系统评价
Pharmaceutics. 2023 Apr 19;15(4):1275. doi: 10.3390/pharmaceutics15041275.
5
Efficacy of curcumin for amelioration of radiotherapy-induced oral mucositis: a preliminary randomized controlled clinical trial.姜黄素改善放射性口腔黏膜炎的疗效：一项初步的随机对照临床试验。
BMC Cancer. 2023 Apr 17;23(1):354. doi: 10.1186/s12885-023-10730-8.
6
Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?提高生物利用度的姜黄素制剂：我们目前从临床试验中学到了什么？
ACS Omega. 2023 Mar 13;8(12):10713-10746. doi: 10.1021/acsomega.2c07326. eCollection 2023 Mar 28.
7
Efficacy of Wholistic Turmeric Supplement on Adenomatous Polyps in Patients with Familial Adenomatous Polyposis-A Randomized, Double-Blinded, Placebo-Controlled Study.整体姜黄补充剂对家族性腺瘤性息肉病患者腺瘤的疗效：一项随机、双盲、安慰剂对照研究。
Genes (Basel). 2022 Nov 22;13(12):2182. doi: 10.3390/genes13122182.
8
Specific metabolic response of patient-derived organoids to curcumin of colorectal cancer.结直肠癌细胞来源的类器官对姜黄素的特定代谢反应。
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jul 1;1203:123260. doi: 10.1016/j.jchromb.2022.123260. Epub 2022 Apr 20.
9
Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer.复发性卵巢癌药物反应和蛋白质生物标志物表达的患者间异质性
Cancers (Basel). 2022 May 3;14(9):2279. doi: 10.3390/cancers14092279.
10
Curcumin and Derivatives in Nanoformulations with Therapeutic Potential on Colorectal Cancer.姜黄素及其纳米制剂在结直肠癌治疗中的潜在应用。
AAPS PharmSciTech. 2022 Apr 19;23(5):115. doi: 10.1208/s12249-022-02268-y.